Inactief instrument

Andere talen Nascent Biotech, Inc. Other OTC

Aandelen

NBIO

US63108Q1013

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Nascent Prepares for Pivotal Phase II Research with Fresh Manufacturing Run	17/04
Nascent Biotech, Inc. Prepares for Pivotal Phase II Research with Fresh Manufacturing Run	16/04
Nascent Collaborates With Hypospray Pharma Announces Collaboration to Develop an Alternative Delivery Mechanism for Patients Who Can Benefit from Pritumumab	19/03
Nascent Biotech, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	14/02
Nascent Biotech and Manhattan Biosolutions Collaborate to Explore Pritumumab Antibody-Drug Conjugates	06/02
Nascent Biotech Receives an Analyst Opinion Suggesting that of the Company is significantly under Valued	10/01
Nascent Biotech Completes Payment of Variable Convertible Note in Full to Eliminate Dilution Risk	20/12
Nascent Biotech, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	09/11
Nascent Biotech to Begin Phase II Clinical Trials for Brain Cancer	22-08-23
Nascent Biotech, Inc. Reports Earnings Results for the First Quarter Ended June 30, 2023	18-08-23
Nascent Biotech, Inc. Auditor Raises 'Going Concern' Doubt	03-07-23
Nascent Biotech, Inc. Reports Earnings Results for the Full Year Ended March 31, 2023	29-06-23
Nastcent Biotech, Inc. and BioRay Pharmaceutical Co Mutually Terminates the License Agreement	30-05-23
Nascent Biotech : Termination of Material Agreement - Form 8-K	30-05-23
NASCENT BIOTECH INC. : Other Events, Financial Statements and Exhibits (form 8-K)	09-05-23
Nascent Biotech, Inc. Announces the Completion of Its Phase1 Clinical Trials	28-02-23
NASCENT BIOTECH INC. : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERTIONS (form 10-Q)	14-02-23
Nascent Biotech, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2022	14-02-23
NASCENT BIOTECH INC. : Other Events, Financial Statements and Exhibits (form 8-K)	26-01-23
Nascent Biotech, Inc. Completes Dosing Requirement in Final Cohort of Phase I Clinical Trial	25-01-23

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Nascent Biotech, Inc. Other OTC

Aandelen

NBIO

US63108Q1013

Andere talen

Filters